Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Tracking Tweets, Blog Posts To Gauge Reach Of Drug Safety Communications

Executive Summary

FDA is in the early stages of developing a plan for how to get the most dissemination bang for its risk communication bucks.

You may also be interested in...



FDA Gets Social, But Not Too Social

FDA is trying multiple channels in social media to communicate drug safety information, but its two-way communication capacity is lower than many would like.

Can Pfizer’s "Virtual Trial" Change The Game, Cut Development Costs?

As drug makers seek ways to reduce the cost of clinical trials, Pfizer thinks the solution could be asking patients to reach into their own pockets – for their cell phones.

Can Pfizer’s "Virtual Trial" Change The Game, Cut Development Costs?

As drug makers seek ways to reduce the cost of clinical trials, Pfizer thinks the solution could be asking patients to reach into their own pockets – for their cell phones.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel